Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Here's How Much $1000 Invested In Novo Nordisk 5 Years Ago Would Be Worth Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 21.31%. Currently, Novo Nordisk has a market capitalization of $251.98 billion.

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022

Dow Jones Up As Powell Gives This Recession Warning; Bitcoin Crumbles Again; 3 Stocks Eye Buy Points

Dow Jones Up As Powell Gives This Recession Warning; Bitcoin Crumbles Again; 3 Stocks Eye Buy Points

The Dow Jones rose despite a recession warning from Fed Chair Jerome Powell. Bitcoin tumbled again. Apple stock rose after a bullish call.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 3.35% on an annualized basis producing an average annual return of 14.11%. Currently, Novo Nordisk has a market capitalization of $238.19 billion.

We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit

A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to help treat obesity. A potential multibillion-dollar market beckons them.

Investors Business Daily

California wants to slash insulin prices by becoming a drugmaker. Can it succeed?

SACRAMENTO, Calif. — California is diving into the prescription drug business, attempting to achieve what no other state has done: produce its own brand of generic insulin and sell it at below-market prices to people with diabetes like Sabrina Caudillo.

Tribune News Service

Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2022

Shortage of diabetes medication Ozempic after TikTok users promote drug for weight loss

Shortage of diabetes medication Ozempic after TikTok users promote drug for weight loss

TGA urges GPs to limit prescriptions to approved use for diabetes management amid surge in off-label demand

The Guardian - AU

Top-Rated Eli Lilly Nears Breakout After FDA Approves Its Next Potential Blockbuster

Top-Rated Eli Lilly Nears Breakout After FDA Approves Its Next Potential Blockbuster

The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout.

Investors Business Daily

Peering Into Novo Nordisk's Recent Short Interest

Peering Into Novo Nordisk's Recent Short Interest

Novo Nordisk's (NYSE:NVO) short percent of float has fallen 20.0% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 0.12% of all regular shares that are available for trading.

Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years

Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.43% on an annualized basis producing an average annual return of 14.2%. Currently, Novo Nordisk has a market capitalization of $253.71 billion.

Here We Go Again: Stock Market Indexes Fade; Meta Platforms Soars, But GDP Falls In Q1

Here We Go Again: Stock Market Indexes Fade; Meta Platforms Soars, But GDP Falls In Q1

While earnings were mainly higher, the U.S. economy shrank in the first quarter.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

IBD Screen Of The Day: This One Snags Four Growth Stocks Near Buy Points

In today's IBD Screen Of The Day, the Stocks That Funds Are Buying filter reveals four compelling growth stocks near buy points of new bases. Three are in the energy field and one is a drugmaker. Novo Nordisk (NVO) has waffled a bit after breaking out above the 117.45 buy…

If You Invested $100 In Novo Nordisk 10 Years Ago, Here's How Much You Would Have Today

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.28% on an annualized basis producing an average annual return of 14.59%. Currently, Novo Nordisk has a market capitalization of $268.66 billion.

Investors Business Daily

IBD Screen Of The Day: Keep An Eye On These Top Global Stocks Near Buy Points

Novo Nordisk will report first-quarter earnings on May 4.

Why Novo Nordisk Shares Are Trading Higher Today

The FDA has approved Novo Nordisk A/S's (NYSE:NVO) 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes. Ozempic is now approved in the US at 0.5 mg,1.0 mg, and 2.0 mg doses to treat type 2 diabetes in adults. Further, Ozempic is indicated to…

Get all your
news in one place.

100’s of premium titles.
One news app.

$1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth This Much

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 2.52% on an annualized basis producing an average annual return of 14.65%. Currently, Novo Nordisk has a market capitalization of $250.29 billion.

Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand

Novo Nordisk A/S (NYSE: NVO) has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug.

Novo Nordisk Posts Upbeat Q4 Earnings, Expects Obesity Drug Shortages May Soon Be Resolved

Novo Nordisk A/S (NYSE: NVO)

Novo Nordisk: Q4 Earnings Insights

Novo Nordisk (NYSE:NVO) reported its Q4 earnings results on Wednesday, February 2, 2022 at 01:30 AM. Here's what investors need to know about the announcement.

1 … 24 25 26 27

People

Alex Oshmyansky

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Prescription Drug

Places

300,712 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play